After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...

WALTHAM, MA - April 23, 2026 - - KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug ...

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...

Insulin resistance is a common extrahepatic manifestation of hepatitis C virus (HCV) infection (HCVi), but its mechanism is poorly understood. While ...

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...

OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from ...

Discover how obakulactone, a natural compound from Phellodendri cortex, eases rheumatoid arthritis symptoms! A new ...

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options ...

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a ...

The U.S. Food and Drug Administration has broadened approval of Teplizumab-developed by Sanofi-to include children as young ...